Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday
Shares of Enanta Pharmaceuticals (NASDAQ: ENTA) were down more than 9% as of 11:45 a.m. on Tuesday after the clinical-stage biotech released fiscal third-quarter earnings on Tuesday. The stock is down more than 62% so far this year.
Enanta focuses on finding small-molecule drugs to treat viral infections and liver diseases. The company's quarterly revenue, all from royalties regarding sales of Mavyret, a hepatitis C therapy sold by AbbVie, fell 3% year over year to $18.9 million. Enanta reported a net loss of $39.1 million, or an earnings per share (EPS) loss of $1.86, compared to a loss of $31.7 million for an EPS loss of $1.53 in the same quarter a year ago.
The company cited increased clinical trial costs for the greater net loss. It said it had $392.5 million in cash, enough to fund operations into midyear in fiscal 2027.
Source Fool.com
Enanta Pharmaceuticals Inc. Aktie
Eine klare Neigung zu Buy-Einschätzungen bei Enanta Pharmaceuticals Inc., ohne Sell-Einschätzungen.
Eine deutliche Steigerung um mehr als 20% ist für Enanta Pharmaceuticals Inc. mit einem Kursziel von 17 € gegenüber 11.5 € zu erwarten.
